MedTrace Logo

Efficacy of Human Chorionic Gonadotropin in Acute GVHD Treatment

NCT06904599 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2025-04-03

No results posted yet for this study

Summary

Graft-versus-host disease is a complication of allogeneic hematopoietic cell transplantation with high morbidity and mortality. The standard treatment is corticosteroids, and based on the response within 3 to 7 days, a second-line therapy is added, which is expensive and not easily accessible. The administration of human chorionic gonadotropin has shown therapeutic effectiveness in 50% of patients in reported clinical cases.

Conditions

  • Acute Graft Versus Host Disease

Interventions

DRUG

Human chorionic gonadotropin (hCG)

2500 IU intramuscular on days 1, 3, and 5 of the protocol. Patients who have at least a partial response by day 7 will receive 3 weekly doses for an additional 4 weeks.

DRUG

Prednisone

Oral prednisone 1 mg/kg/day for 14 days

DRUG

Dexamethasone

IV dexamethasone 0.15 mg/kg/day for 14 days

Sponsors & Collaborators

  • Marisa Romero Martínez

    collaborator UNKNOWN

  • Dr. José Carlos Jaime Perez

    collaborator UNKNOWN

  • Dr. David Gómez Almaguer

    collaborator UNKNOWN

  • Dra. Consuelo Mancias Guerra

    collaborator UNKNOWN

  • Dr. Andrés Gómez de León

    collaborator UNKNOWN

  • Dra. Olga Graciela Catú Rodríguez

    collaborator UNKNOWN

  • Dra. Perla Colunga Pedraza

    collaborator UNKNOWN

  • Dra. Michelle Morcos Sandino

    collaborator UNKNOWN

  • Hospital Universitario Dr. Jose E. Gonzalez

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-02-01
Primary Completion
2026-01-31
Completion
2026-01-31

Countries

  • Mexico

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06904599 on ClinicalTrials.gov